Solventum Corp (SOLV) — SEC Financial Statements & Analysis

Solventum Corp (SOLV) is a surgical & medical instruments & apparatus company, incorporated in DE. Solventum Corp trades on NYSE as: SOLV. Solventum Corp (SOLV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Solventum Corp carries a market cap of $13.32B, a P/E ratio of 9.29x, a P/B ratio of 2.78x, a P/S ratio of 1.60x, an enterprise value of $18.00B, and an EV/EBITDA multiple of 6.97x. On profitability, it posts a gross margin of 54.69%, an operating margin of 24.99%, a net margin of 17.26%, a Return on Equity (ROE) of 33.96%, a Return on Assets (ROA) of 9.78%, and a Return on Invested Capital (ROIC) of 16.92%. Per share, it reports EPS of $8.30, diluted EPS of $8.27, free cash flow per share of $-0.68, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -0.93% year-over-year, net income growth of 277.37% year-over-year, and EPS growth of 280.43% year-over-year. On the balance sheet, it maintains a current ratio of 1.02x, a quick ratio of 0.74x, working capital of $78.00M, a debt-to-equity ratio of 1.97x, a debt ratio of 0.66, an interest coverage ratio of 7.81x, free cash flow of $-118.00M (TTM), and net debt of $4.68B. Figures sourced from SEC EDGAR.

Market Cap

$13.32B

P/E TTM

9.29x

EPS TTM

$8.30

P/B TTM

2.78x

ROE TTM

33.96%

ROA TTM

9.78%

Debt To Equity

1.97x

Free Cash Flow TTM

$-118.00M

Net Revenue TTM Growth 1Y

-0.93%

Data as of 2026-06-30 · Source: SEC EDGAR